{"nctId":"NCT02305446","briefTitle":"Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.","startDateStruct":{"date":"2014-12"},"conditions":["Meningitis, Meningococcal, Serogroup B"],"count":55,"armGroups":[{"label":"rMenB+OMV NZ","type":"EXPERIMENTAL","interventionNames":["Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine"]}],"interventions":[{"name":"Meningococcal (group B) multicomponent recombinant adsorbed vaccine","otherNames":["rMenB+OMV NZ"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Individuals of 18 through 50 years of age on the day of informed consent;\n2. Individuals who had voluntarily given written informed consent after the nature of the study had been explained according to local regulatory requirements, prior to study entry;\n3. Individuals who could comply with study procedures including follow-up;\n4. Males, females of non-childbearing potential or females of childbearing potential who are using an effective birth control method.\n\nExclusion Criteria:\n\n1. Progressive, unstable or uncontrolled clinical conditions;\n2. Hypersensitivity, including allergy, to any component of vaccines or medical equipment whose use is foreseen in this study;\n3. Abnormal function of the immune system;\n4. Chronic clinical significant conditions;\n\n4\\. Been administered any group B meningococcal vaccine at any time prior to informed consent; 5. Current or previous, confirmed or suspected disease caused by N.meningitidis.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Unsolicited Adverse Events (AEs).","description":"Safety was assessed as the number of the subjects who reported unsolicited AEs following vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Adult Volunteers Whose Blood Can be Used as a Reference in Serum Bactericidal Activity (SBA) Test.","description":"The number of identified healthy adult volunteers with pre and postvaccination blood donations were summarized to establish a control sera panel to be used as a reference in SBA test.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":55},"commonTop":[]}}}